Perspective Therapeutics (NYSEAMERICAN:CATX) Hits New 1-Year High at $1.62

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) reached a new 52-week high on Tuesday . The company traded as high as 1.62 and last traded at 1.60, with a volume of 1449231 shares. The stock had previously closed at 1.53.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CATX. Oppenheimer reaffirmed an “outperform” rating and issued a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. B. Riley upped their price objective on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a report on Tuesday, April 9th.

Perspective Therapeutics Price Performance

The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02. The stock has a market cap of $991.89 million, a P/E ratio of -16.90 and a beta of 1.56.

Insider Buying and Selling at Perspective Therapeutics

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.72% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Several large investors have recently added to or reduced their stakes in CATX. Bank of New York Mellon Corp acquired a new stake in Perspective Therapeutics during the third quarter worth approximately $42,000. Perkins Capital Management Inc. acquired a new stake in Perspective Therapeutics in the third quarter valued at approximately $731,000. HighTower Advisors LLC acquired a new stake in Perspective Therapeutics in the third quarter valued at approximately $314,000. Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after acquiring an additional 50,000 shares during the period. Finally, Simplicity Wealth LLC acquired a new stake in Perspective Therapeutics in the first quarter valued at approximately $40,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.